Create a free QxMD account to receive personalized paper recommendations, relevant to your practice.

JOURNAL ARTICLE

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters

Hiltrud Brauch, Werner Schroth, Matthew P Goetz, Thomas E Mürdter, Stefan Winter, James N Ingle, Matthias Schwab, Michel Eichelbaum

Journal of Clinical Oncology 2013 January 10, 31 (2): 176-80

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. James M Rae, Meredith Regan, Brian Leyland-Jones, Daniel F Hayes, Mitch Dowsett Journal of Clinical Oncology 2013 July 20, 31 (21): 2753-5

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell'orto, Maria Olivia Biasi, Beat Thürlimann, Maria B Lyng, Henrik J Ditzel, Patrick Neven, Marc Debled, Rudolf Maibach, Karen N Price, Richard D Gelber, Alan S Coates, Aron Goldhirsch, James M Rae, Giuseppe Viale Journal of the National Cancer Institute 2012 March 21, 104 (6): 441-51

CYP2D6 and tamoxifen: DNA matters in breast cancer. Janelle M Hoskins, Lisa A Carey, Howard L McLeod Nature Reviews. Cancer 2009, 9 (8): 576-86

Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Hiltrud Brauch, Matthias Schwab British Journal of Clinical Pharmacology 2014, 77 (4): 695-703

Why should results from metastatic trials no longer matter for early-stage disease? Anne-Sophie Dieudonné, Diether Lambrechts, Hans Wildiers, Patrick Neven Journal of Clinical Oncology 2013 July 20, 31 (21): 2753

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. Paul D P Pharoah, Jean Abraham, Carlos Caldas Journal of the National Cancer Institute 2012 August 22, 104 (16): 1263-4; author reply 1266-8

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer. Per Damkier British Journal of Clinical Pharmacology 2014, 78 (2): 431-2

Reply to A.-S. Dieudonné et al and J.M. Rae et al. Hiltrud Brauch, Werner Schroth, Matthew P Goetz, Thomas E Mürdter, Stefan Winter, James N Ingle, Matthias Schwab, Michel Eichelbaum Journal of Clinical Oncology 2013 July 20, 31 (21): 2755-6

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply. Hiltrud Brauch, Matthias Schwab British Journal of Clinical Pharmacology 2014, 78 (2): 433-4

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer. Cindy Gaston, Jill Kolesar Clinical Advances in Hematology & Oncology: H&O 2008, 6 (11): 825-33

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips